Martel ML, Driver BE, Miner JR, et al. - Via a randomized, double‐blind trial, researchers sought to compare the effectiveness and safety of intramuscular droperidol, ziprasidone, and lorazepam for acute agitation in the ED. A total of 115 patients were enrolled and randomized to receive 5 mg of droperidol, 10 mg of ziprasidone, 20 mg of ziprasidone, or 2 mg of lorazepam intramuscularly. Outcomes suggest greater effectiveness of droperidol than lorazepam or either dose of ziprasidone for the treatment of acute agitation in the ED as well as its correlation with fewer episodes of respiratory depression.